Erythropoietin in Cardiac Surgery

Robert E. Helm, Jeffrey P Gold, Todd K. Rosengart, John A. Zelano, O. Wayne Isom, Karl H. Krieger

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Abstract Erythropoietin is the primary growth factor for red blood cells. A glycoprotein hormone synthesized by the kidneys, erythropoietin serves to increase red blood cell production in response to tissue hypoxia. It exerts its effect by increasing the numbers of erythroid progenitor cells in the bone marrow, and by increasing the rate at which their development is accomplished. With the introduction of recombinant erythropoietin in 1987, an important pharmacological agent became available for the manipulation of erythropoiesis. While used primarily for the treatment of the anemia of renal failure, recombinant erythropoietin has also shown usefulness in treating other types of anemias in which the endogenous erythropoietin response is insufficient. Perioperative use of the drug grew as a natural extension of this, and erythropoietin has been applied to correct preoperative anemia, augment autologous blood donation, and improve postoperative red cell recovery. Analysis of these perioperative clinical studies reveals success in these areas, but it also reveals that closer attention to the physiology of the natural response, and to the pharmacology of the recombinant product, might significantly improve results. Such an improvement in efficacy is both desirable and necessary when use of the drug is viewed in the setting of today's changing health care environment. By optimizing dosing schedules and targeting the drug to those most at risk for red cell transfusion, recombinant erythropoietin will likely become an important tool in efforts to achieve the elusive goal of bloodless cardiac surgery.

Original languageEnglish (US)
Pages (from-to)579-606
Number of pages28
JournalJournal of Cardiac Surgery
Volume8
Issue number5
DOIs
StatePublished - Jan 1 1993

Fingerprint

Erythropoietin
Thoracic Surgery
Anemia
Bloodless Medical and Surgical Procedures
Erythrocytes
Pharmacology
Erythroid Precursor Cells
Erythropoiesis
Drug Delivery Systems
Blood Donors
Pharmaceutical Preparations
Renal Insufficiency
Intercellular Signaling Peptides and Proteins
Glycoproteins
Appointments and Schedules
Bone Marrow
Hormones
Delivery of Health Care
Kidney

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Helm, R. E., Gold, J. P., Rosengart, T. K., Zelano, J. A., Isom, O. W., & Krieger, K. H. (1993). Erythropoietin in Cardiac Surgery. Journal of Cardiac Surgery, 8(5), 579-606. https://doi.org/10.1111/j.1540-8191.1993.tb00416.x

Erythropoietin in Cardiac Surgery. / Helm, Robert E.; Gold, Jeffrey P; Rosengart, Todd K.; Zelano, John A.; Isom, O. Wayne; Krieger, Karl H.

In: Journal of Cardiac Surgery, Vol. 8, No. 5, 01.01.1993, p. 579-606.

Research output: Contribution to journalArticle

Helm, RE, Gold, JP, Rosengart, TK, Zelano, JA, Isom, OW & Krieger, KH 1993, 'Erythropoietin in Cardiac Surgery', Journal of Cardiac Surgery, vol. 8, no. 5, pp. 579-606. https://doi.org/10.1111/j.1540-8191.1993.tb00416.x
Helm RE, Gold JP, Rosengart TK, Zelano JA, Isom OW, Krieger KH. Erythropoietin in Cardiac Surgery. Journal of Cardiac Surgery. 1993 Jan 1;8(5):579-606. https://doi.org/10.1111/j.1540-8191.1993.tb00416.x
Helm, Robert E. ; Gold, Jeffrey P ; Rosengart, Todd K. ; Zelano, John A. ; Isom, O. Wayne ; Krieger, Karl H. / Erythropoietin in Cardiac Surgery. In: Journal of Cardiac Surgery. 1993 ; Vol. 8, No. 5. pp. 579-606.
@article{5f5d13a72f504ff486e3718ae55ed276,
title = "Erythropoietin in Cardiac Surgery",
abstract = "Abstract Erythropoietin is the primary growth factor for red blood cells. A glycoprotein hormone synthesized by the kidneys, erythropoietin serves to increase red blood cell production in response to tissue hypoxia. It exerts its effect by increasing the numbers of erythroid progenitor cells in the bone marrow, and by increasing the rate at which their development is accomplished. With the introduction of recombinant erythropoietin in 1987, an important pharmacological agent became available for the manipulation of erythropoiesis. While used primarily for the treatment of the anemia of renal failure, recombinant erythropoietin has also shown usefulness in treating other types of anemias in which the endogenous erythropoietin response is insufficient. Perioperative use of the drug grew as a natural extension of this, and erythropoietin has been applied to correct preoperative anemia, augment autologous blood donation, and improve postoperative red cell recovery. Analysis of these perioperative clinical studies reveals success in these areas, but it also reveals that closer attention to the physiology of the natural response, and to the pharmacology of the recombinant product, might significantly improve results. Such an improvement in efficacy is both desirable and necessary when use of the drug is viewed in the setting of today's changing health care environment. By optimizing dosing schedules and targeting the drug to those most at risk for red cell transfusion, recombinant erythropoietin will likely become an important tool in efforts to achieve the elusive goal of bloodless cardiac surgery.",
author = "Helm, {Robert E.} and Gold, {Jeffrey P} and Rosengart, {Todd K.} and Zelano, {John A.} and Isom, {O. Wayne} and Krieger, {Karl H.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1111/j.1540-8191.1993.tb00416.x",
language = "English (US)",
volume = "8",
pages = "579--606",
journal = "Journal of Cardiac Surgery",
issn = "0886-0440",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Erythropoietin in Cardiac Surgery

AU - Helm, Robert E.

AU - Gold, Jeffrey P

AU - Rosengart, Todd K.

AU - Zelano, John A.

AU - Isom, O. Wayne

AU - Krieger, Karl H.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Abstract Erythropoietin is the primary growth factor for red blood cells. A glycoprotein hormone synthesized by the kidneys, erythropoietin serves to increase red blood cell production in response to tissue hypoxia. It exerts its effect by increasing the numbers of erythroid progenitor cells in the bone marrow, and by increasing the rate at which their development is accomplished. With the introduction of recombinant erythropoietin in 1987, an important pharmacological agent became available for the manipulation of erythropoiesis. While used primarily for the treatment of the anemia of renal failure, recombinant erythropoietin has also shown usefulness in treating other types of anemias in which the endogenous erythropoietin response is insufficient. Perioperative use of the drug grew as a natural extension of this, and erythropoietin has been applied to correct preoperative anemia, augment autologous blood donation, and improve postoperative red cell recovery. Analysis of these perioperative clinical studies reveals success in these areas, but it also reveals that closer attention to the physiology of the natural response, and to the pharmacology of the recombinant product, might significantly improve results. Such an improvement in efficacy is both desirable and necessary when use of the drug is viewed in the setting of today's changing health care environment. By optimizing dosing schedules and targeting the drug to those most at risk for red cell transfusion, recombinant erythropoietin will likely become an important tool in efforts to achieve the elusive goal of bloodless cardiac surgery.

AB - Abstract Erythropoietin is the primary growth factor for red blood cells. A glycoprotein hormone synthesized by the kidneys, erythropoietin serves to increase red blood cell production in response to tissue hypoxia. It exerts its effect by increasing the numbers of erythroid progenitor cells in the bone marrow, and by increasing the rate at which their development is accomplished. With the introduction of recombinant erythropoietin in 1987, an important pharmacological agent became available for the manipulation of erythropoiesis. While used primarily for the treatment of the anemia of renal failure, recombinant erythropoietin has also shown usefulness in treating other types of anemias in which the endogenous erythropoietin response is insufficient. Perioperative use of the drug grew as a natural extension of this, and erythropoietin has been applied to correct preoperative anemia, augment autologous blood donation, and improve postoperative red cell recovery. Analysis of these perioperative clinical studies reveals success in these areas, but it also reveals that closer attention to the physiology of the natural response, and to the pharmacology of the recombinant product, might significantly improve results. Such an improvement in efficacy is both desirable and necessary when use of the drug is viewed in the setting of today's changing health care environment. By optimizing dosing schedules and targeting the drug to those most at risk for red cell transfusion, recombinant erythropoietin will likely become an important tool in efforts to achieve the elusive goal of bloodless cardiac surgery.

UR - http://www.scopus.com/inward/record.url?scp=0027442450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027442450&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8191.1993.tb00416.x

DO - 10.1111/j.1540-8191.1993.tb00416.x

M3 - Article

VL - 8

SP - 579

EP - 606

JO - Journal of Cardiac Surgery

JF - Journal of Cardiac Surgery

SN - 0886-0440

IS - 5

ER -